Early COVID-19 infection after lung transplantation in a patient with cystic fibrosis

Athanazio, Rodrigo Abensur; Costa, André Nathan; Carraro, Rafael Medeiros; González, D.; Rached, Samia Zahi; Samano, Marcos Naoyuki; Teixeira, Ricardo Henrique de Oliveira Braga; Campos, Sílvia Vidal

doi:10.6061/clinics/2020/e2274

Cited by 5 publications

(2 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…1 . Most included studies were case reports (n=89) [24] , [25] , [26] , [27] , [28] , [29] , [30] , [31] , [32] , [33] , [34] , [35] , [36] , [37] , [38] , [39] , [40] , [41] , [42] , [43] , [44] , [45] , [46] , [47] , [48] , [49] , [50] , [51] , [52] , [53] , [54] , [55] , [56] , [57] , [58] , [59] , [60] , [61] , [62] , [63] , [64] , [65] , [66] , [67] , [68] , [69] , [70] , [71] , [72] , [73] , [74] , [75] , [76] , [77] , [78] , [79] , [80] , [81] , [82] , [83] , [84] , [85] , [86] , [87] , [88] ...…”

Section: Resultsunclassified

SARS-CoV-2 in Solid Organ Transplant Recipients: A Structured Review of 2020

Quante

Brake

Tolios

et al. 2021

Transplantation Proceedings

View full text Add to dashboard Cite

Background : The SARS-CoV-2 pandemic is challenging health systems all over the world. Particularly high-risk groups show considerable mortality rates after infection. In 2020, an inexorable number of case reports, case series and ultimately various systematic reviews have been published reporting on morbidity and mortality risk of SARS-CoV-2 in solid organ transplant (SOT) recipients. However, this vast array of publications resulted in an increasing complexity of the field, overwhelming even the expert reader. Methods : We performed a structured literature review comprising electronic databases, transplant journals and included literature from previous systematic reviews covering the entire year 2020. From 164 included articles we identified 3451 cases of SARS-CoV-2 infected SOT recipients. Results : Infections resulted in a hospitalization rate of 84% and 24% intensive care unit admissions (ICU) in the included patients. Whereas 53.6% of patients were reported to have recovered, cross-sectional overall mortality reported after COVID-19 was at 21.1%. Synoptic data concerning immunosuppressive medication attested to the reduction or withdrawal of antimetabolites (81.9%) and calcineurin inhibitors (48.9%) as a frequent adjustment. In contrast, steroids were reported to be increased in 46.8% of SOT patients. Conclusions : COVID-19 in SOT recipients is associated with high morbidity and mortality worldwide. Conforming with current guidelines, modifications of immunosuppressive therapies mostly comprised a reduction or withdrawal of antimetabolites and calcineurin inhibitors, while frequently maintaining or even increasing steroids. Here, we provide an accessible overview to the topic and synoptic estimates of expectable outcomes regarding in-hospital mortality of SOT patients diseased with COVID-19.

show abstract

Section: Resultsunclassified

SARS-CoV-2 in Solid Organ Transplant Recipients: A Structured Review of 2020

Quante

Brake

Tolios

et al. 2021

Transplantation Proceedings

View full text Add to dashboard Cite

show abstract

“…(5) Vários relatos e séries de casos confirmaram a associação de transplante pulmonar em pacientes com FC e formas graves de COVID-19. (6)(7)(8) Esses dados reforçam que a imunossupressão relacionada ao transplante seria um fator contribuinte para um maior risco de complicações do que a própria FC. Entretanto, estamos longe de assumir que não há riscos relacionados à COVID-19 para pacientes com FC.…”

unclassified

Is cystic fibrosis a risk factor for COVID-19 infection or related complications?

Athanazio

2022

J Bras Pneumol.

Self Cite

View full text Add to dashboard Cite

COVID-19 in Recent Lung Transplant Recipients: Clinical Outcomes and Management Strategies

Zimmermann

Glueck

Fertmann

et al. 2022

Transplantation Proceedings

View full text Add to dashboard Cite

Background Covid-19 causes a wide range of symptoms, with particularly high risk of severe respiratory failure and death in patients with predisposing risk factors such as advanced age or obesity. Recipients of solid organ transplants, and in particular lung transplantation, are more susceptible to viral infection due to immune suppressive medication. As little is known about the SARS-CoV-2 infection in these patients, this study was undertaken to describe outcomes and potential management strategies in early COVID-19 infection early after lung transplantation. Methods We describe the incidence and outcome of COVID-19 in a cohort of recent lung transplant recipients in Munich. Six of 186 patients who underwent lung transplantation in the period between March 2019 until March 2021 developed COVID-19 within the first year after transplantation. We documented the clinical course and laboratory changes for all patients showing differences in the severity of the infection with COVID-19 and their outcomes. Results Three of six SARS-CoV-2 infections were hospital-acquired and the patients were still in inpatient treatment following lung transplantation. All patients suffered from symptoms. One patient did not received antiviral therapy. Remdesivir was prescribed in four patients and the remaining patient received remdesivir, bamlanivimab and convalescent plasma. Conclusion COVID-19 does not appear to cause milder disease in lung transplant recipients compared to the general population. Immunosuppression is potentially responsible for the delayed formation of antibodies and their premature loss. Several comorbidities and a general poor preoperative condition showed an extended hospital stay.

show abstract

Early COVID-19 infection after lung transplantation in a patient with cystic fibrosis

Cited by 5 publications

References 6 publications

SARS-CoV-2 in Solid Organ Transplant Recipients: A Structured Review of 2020

SARS-CoV-2 in Solid Organ Transplant Recipients: A Structured Review of 2020

Is cystic fibrosis a risk factor for COVID-19 infection or related complications?

COVID-19 in Recent Lung Transplant Recipients: Clinical Outcomes and Management Strategies

Contact Info

Product

Resources

About